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Highlights:  
 High Sulf1/Sulf2 expression in active osteoblasts with reduction in osteocytes. 
 High variability in Sulf1/Sulf2 expression in articular chondrocytes. 
 Hypertrophic chondrocytes in growing and healing bone express high levels of 
Sulf2 but not Sulf1. 
 High Sulf2 expression in growing and healing bone closely correlates with 
Hedgehog signalling. 
ABSTRACT: SULF1/SULF2 enzymes regulate cell signalling that impacts the growth 
and differentiation of many tissues. To determine their possible role in cartilage and 
bone growth or repair, their expression was examined during development and bone 
fracture healing using RT-PCR and immunochemical analyses. Examination of 
epiphyseal growth plates revealed differential, inverse patterns of SULF1 and SULF2 
expression, with the former enriched in quiescent and the latter in hypertrophic 
chondrocyte zones.  Markedly higher levels of both SULFs, however, were expressed 
in osteoblasts actively forming bone when compared with proliferating pre-osteoblasts 
in the periosteum or the entombed osteocytes which express the lowest levels. The 
increased Sulf1 and Sulf2 expression in differentiating osteoblasts was further 
confirmed by RT PCR analysis of mRNA levels in rat calvarial osteoblast cultures.  
 
SULF1 and SULF2 were expressed in most fetal articular chondrocytes but down-
regulated in a larger subset of cells in the postnatal articular cartilage. Unlike adult 
articular chondrocytes, SULF1/SULF2 expression varied markedly in postnatal 
hypertrophic chondrocytes in the growth plate, with very high SULF2 expression 
compared with SULF1 apparent during neonatal growth in both primary and secondary 
centres of ossification. Similarly, hypertrophic chondrocytes expressed greatly higher 
levels of SULF2 but not SULF1 during bone fracture healing. SULF2 expression unlike 
SULF1 also spread to the calcifying matrix around the hypertrophic chondrocytes 
indicating its possible ligand inhibiting role through HSPG desulfation.  Higher levels of 
SULF2 in both developing and healing bone closely correlated with parallel increases 
in hedgehog signalling analysed by ptc1 receptor expression. 
 
INTRODUCTION:  SULF1/SULF2 enzymes are critical for modulating cell signalling 
pathways that require heparan sulfate proteoglycan (HSPG) as a co-factor facilitating 
ligand-receptor interactions (Dhoot et al. 2001; Morimoto-Tomita et al. 2002; Rosen 
and Lemjabbar-Alaoui 2010). HSPG function is dependent on the sulfation status of 
its heparan sulfate (HS) side chains which comprise of repeating disaccharide units 
of uronic acid linked to glucosamine (Lamanna et al. 2006). The disaccharide units are 
selectively sulfated at the N, 3-O, and 6-O positions of glucosamine and the 2-O 
position of iduronic acid residues by sulfotransferases in the Golgi apparatus (Merry 
and Gallagher 2002). HSPGs are secreted to the cell surface or the extracellular 
matrix (ECM) where they have signalling and matrix functions, respectively (Stringer 
and Gallagher 1997). The sulfation pattern of HS chains, however, is further fine-
tuned extracellularly by the activities of SULF1 and SULF2 enzymes (Dhoot et al. 
2001; Morimoto-Tomita et al. 2002). These are members of the sulfatase gene family 
that regulate the activities of many signalling pathways. The ability of SULFs to 
regulate such pathways relies on highly specific removal of 6-O-sulfates from HS 
chains. This leads to inhibition of 6-O sulfate requiring ligands, such as fibroblast 
growth factors (FGF), hepatocyte growth factor (HGF) and vascular endothelial 
growth factor (VEGF) but also to promotion of other signalling pathways such as 
those involving Glial cell-derived neurotrophic factor (GDNF) and Wnts. Some further 
studies have also identified splice variants of both Sulf1 and Sulf2 genes in avian as 
well as human tissues (Sahota and Dhoot 2009; Gill et al. 2011; Gill et al. 2012).  
While tumour tissues express multiple splice variants of both Sulf1 and Sulf2, normal 
tissues so far have been described to express only  a full length and a single shorter 
splice variant for both these genes (Gill et al. 2011; Gill et al. 2012). 
Many signalling pathways including BMPs, FGFs, Wnts, IGFs and Hedgehog are 
recognised to orchestrate important roles in bone development, bone remodelling 
and fracture repair (Kronenberg 2003). For example, canonical Wnt signalling has 
been shown to promote progenitor cell differentiation towards the osteoblast and 
chondrocyte lineage in developing skeletal elements whereas hedgehog signalling 
regulates chondrocyte hypertrophy during endochondral ossification.  Many BMPs 
and their receptors are also expressed during bone formation although BMPs and 
FGFs have opposite effects on chondrocyte differentiation. The cartilage anlagen 
enlarge by chondrocyte proliferation and hypertrophy and matrix production which, in 
turn, drives bone growth; these processes are also recapitulated in growth plates 
during bone lengthening as well as during bone fracture repair. The pace of bone 
elongation is also driven by the orientation of the hypertrophic chondrocytes; a 
process regulated by hedgehog signalling (Choi et al. 2012). It is evident that growth 
factors play an important role in the rapid regeneration of bone and cartilage that 
takes place during fracture repair and that its complexity requires coordination of a 
number of the signalling pathways that regulate skeletal cell proliferation, matrix 
synthesis, and tissue differentiation.  
The aim of this study was to examine the expression patterns of both SULF1 and 
SULF2 enzymes in skeletal tissues during development, growth and remodelling to 
investigate whether their expression patterns are consistent with regulatory roles in 
these processes. We also examined the bone healing process using an experimental 
rat femur fracture model to determine whether the patterns of expression of the 
extracellular SULF1/SULF2 enzymes may identify key events for accelerating this 
vital process by regulating their activities.  Our data reveal elevated levels of SULF1 
and 2 expression in fully differentiated osteoblasts and osteoclasts.  We also 
observed high levels of SULF2, but not SULF1 in hypertrophic chondrocytes during 
development as well as fracture repair. 
 
MATERIALS AND METHODS: 
Fracture repair: Osteotomy, in accordance with UK government, Home Office 
regulations, was performed as previously described (Smitham et al. 2014). This work 
was conducted under a project licence granted by the UK Home Office and approved 
by the College’s Ethics and Welfare Committee. On study Day 0, an osteotomy in 
the left femora of 12 week old male Wistar rat followed by stabilisation using external 
fixator pins attached to a mono-fixator frame. The external fixator system used in this 
protocol comprised two metal blocks, of either aluminium or titanium alloy, linked to 
two cylindrical stainless steel bars. The bars were anchored in one block, the other 
incorporating linear bearings allowing it to slide along the bars, thus permitting 
alteration of the osteotomy gap width. Briefly, the fixator was applied to the 
craniolateral aspect of the femur using four threaded M1.2 stainless steel pins. 
Surgery was performed under general anaesthesia (ketamine 75 mg/kg and xylazine 
10 mg/kg) and or appropriate gaseous anaesthesia using aseptic techniques. 
Consistent positioning of the fixator pins was ensured using a drill locator template. A 
bone-fixator distance of 8 mm was created with a precision spacer. After pin 
placement, a transverse osteotomy was created midway between the proximal and 
distal pins using an oscillating diamond bone saw, with saline irrigation throughout. 
The bone fragments were distracted to leave an osteotomy gap of 0.5 mm, this being 
provided using a precision spacer, and was maintained by locking the fixator blocks 
on to the connecting bars. Radiographs of the operation site were taken before 
recovery from anaesthesia. 
Immunofluorescence and immunoperoxidase staining of paraffin sections: The 
tissues for sectioning were fixed in 4% paraformaldehyde for 2-5 days at room 
temperature before demineralisation in EDTA followed by xylene clearance and 
paraffin embedding. The specificities of the SULF1 antibody C for total SULF1 and 
SULF2 antibody D for total SULF2 have been described previously (Sahota and 
Dhoot 2009; Gill et al. 2011; Gill et al. 2012).  Rabbit anti Ptc1 antibody was 
purchased from Millipore.  Immunofluorescence was used to stain paraffin sections 
of normally developing and bone fracture tissues fixed in 4% PFA and decalcified in 
EDTA. Tissue sections were pre-treated with ProK for 30 minutes at 37oC and 
incubation with permeabalisation buffer for 15 minutes at room temperature followed 
by incubation with 10% fetal calf serum (FCS) before incubation with primary 
antibodies against SULF1 or SULF2 or ptc1. The binding of rabbit primary antibodies 
to SULF1 and SULF2 and ptc1 was detected using streptavidin Alexa Fluor 594 or 
Alexa Fluor 488 fluorochrome bound to biotin-linked goat anti rabbit 
immunoglobulins. Sections treated with pre-immune rabbit sera were similarly 
incubated with fluorochrome-labelled secondary antibodies as controls. Primary 
antibodies, SULF1 antibody C was diluted 1/200, SULF2 antibody D as 1/100, while 
rabbit anti ptc1 was diluted 1/300.  Goat anti rabbit immunoglobulins secondary 
antibodies and both fluorochromes were diluted 1/400. All primary antibody reactions 
were incubated overnight at 4°C followed by secondary antibody incubations for 1 
hour each at room temperature. Following 4 PBS washes between and after each 
incubation, labelled tissue sections were mounted in polyvinyl alcohol mounting 
medium with DABCO and  2.5 μg/ml DAPI for nuclear visualisation and 
photographed using a Leica DM4000B fluorescent microscope.  Most tissue sections 
were stained using immunofluorescent procedure but an immunoperoxidase staining 
was also used initially for some tissue sections (Figure 1) to confirm 
immunofluorescent staining that included blocking endogenous peroxidase activity 
by 3% H2O2 for 30 minutes before incubation with primary antibody following pre-
incubation with 10% FCS as described previously  
 
Cell culture and tissue samples:  
 
Rat calvaria cultures: Primary osteoblasts from rat were prepared by sequential 
enzyme digestion of rat calvarial bones from 2-day-old Sprague-Dawley rats, as 
previously described (Shah et al. 2010). Following the first two digests that were 
discarded, the cells from the 3rd digest were resuspended in DMEM (Staines et al. 
2012) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 
mg/ml streptomycin and 0.25 mg/ml amphotericin as previously described (Shah M 
et al 2010). Cells were cultured for 2–4 days at 37°C, 5% CO2 in 75 cm
2 flasks until 
they reached confluence. Such rat primary cells were then sub-cultured into 6-well 
plates in DMEM supplemented with 2 mM β-glycerophosphate, 50 mg/ml ascorbic 
acid and 10nM dexamethasone with half medium changes every 3 days until day 21.  
Osteoblast differentiation was measured by quantification of 1) mineralised bone 
nodules stained with alizarin red (1% solution in water) for 5 min and 2) alkaline 
phosphatase (ALP) activity which is greatly enhanced during in vitro bone formation. 
ALP activity was determined by Fast-Blue staining after fixing the cells with neutral 
buffered formalin. Cells were incubated in ALP staining solution for 30 min and 
washed with deionized water before imaging. 
 
ATDC5 cell culture: Chondrogenic ATDC5 cells (Riken Cell Bank, Ibaraki, Japan) 
were cultured in a differentiation medium [DMEM/F-12 (1:1) with GlutaMAX I 
containing 5% fetal bovine serum (FBS), 1% insulin transferrin and selenium, 1% 
sodium pyruvate and 0.5% gentamicin (Invitrogen, Paisley, UK)] at a density of 6,000 
cells/cm2 in multi-well plates (Iwaki Cell Biology; Sterilin, Feltham, UK) as described 
previously (Newton et al. 2012; Staines et al. 2012). Cells were left for 6 days to 
reach confluency at which point the medium was supplemented with 10 mM βGP 
and 50μg/ml L-ascorbate-2-phosphate (ascorbic acid). Cells were incubated in a 
humidified atmosphere (37°C, 5% CO2) for up to 34 days and the medium was 
changed every second or third day.  
Human skeletal tissues: Primary human osteoblast cell cultures were prepared 
from bone segments taken during routine shoulder operations at the Hospital of St. 
John and St. Elizabeth, London following patient consent before each operation as 
previously described (Clarkin et al. 2008). Samples of human articular cartilage from 
different age groups were also obtained following patient consent before each 
operation within 6 h of surgery from weight-bearing regions of femoral condyles from 
patients undergoing amputation or joint replacement for osteosarcoma or 
chondrosarcoma distant from the joint, and in all cases, joints were not involved in 
the tumor pathology as previously described (Hickery et al. 2003). 
 
RT PCR and qPCR: RNA from ATDC5 cell cultures and cell cultures of rat calvaria 
was prepared using an RNeasy mini kit (Invitrogen) according to the manufacturer's 
instructions. The RNA from different skeletal elements was prepared following the 
removal of muscle, and the cartilaginous ends of the bones and centrifugation of the 
bone shafts for 5000rpm for 2 minutes to remove the marrow before snap-freezing in 
liquid nitrogen.  Such frozen tissues were pulverized under liquid nitrogen using a 
mortar and pestle and lysed in Qiazol lysis reagent (Qiagen Ltd., Crawley, UK).  
Total RNA was extracted from lysed samples using RNeasy mini kit (QIAGEN, 
Crawley, UK). RNA integrity of samples was assessed by electrophoresis using 
ethidium bromide staining and by OD260/OD280 nm absorption ratio (>1.95). Total 
RNA was reverse transcribed with SuperScript II RNase reverse transcriptase 
(Invitrogen), using random primers (Invitrogen, Paisley, UK) for RT PCR and qPCR 
analysis. Real-time qPCR was carried out as previously described (Zaman G 2012) 
using QuantiTect SYBR green PCR kit and Opticon 2 LightCycler (MJ Research, 
Waltham, MA, USA).  The expression levels of Sulf1 and Sulf2 were normalised to 
the reference gene 18s rRNA. RT PCR was carried out using Sigma PCR kit. PCR 
Primers used in this study were: 
 
Human Sulf1 (catalytic domain)                                                                                
=5’-CGAGGTTCAGAGGACGGATA-3’                                                                               
=5’-GCCTCTCCACAGAATCATCC-3’ 
Human Sulf1 (hydrophilic domain)                                                                                 
=5’-TTGTCCATACTCGGCAGACA-3’                                                                                                                    
=5’-TCCCATCCATCCCATAACTG-3’ 
Human Sulf2 (catalytic domain)                                                                                       
=5′-CAACTGTGTTCTCCCTGCTGGGT-3′                                                                   
=5′-CTGGAGCATGTTGGTGAATTCC-3’  
Human Sulf2 (hydrophilic domain)                                                                                 
= 5’-GCCAACCCCATTAAAGTGAC-3’                                                                                                                          
=5’-TGCATTCATCAGCTGGTAGG-3’ 
Mouse Sulf1 (catalytic domain)                                                                                        
=5′-ATGAAGTATTCCCTCTGGGCTCTG-3′;                                                                  
=5′-CAATGTGGTAGCCGTGGTCC-3′  
 
Mouse Sulf 2 (catalytic domain)                                                                                          
=5′-ATGGCACCCCCTGGCCTGCCACTAT-3′                                                                    
=5′-CATAGACTTGCCCTTCACCAGCCC-3′  
 
Human β- actin                                                                                                                  
=5’-CTATGAGCTGCCTGACGGTC-3’                     
=5’-AGTTTCATGGATGCCACAGG-3’ 
 
Human Cyclin D1                                                                                                            
=5’- TCATGGCTGAAGTCACCTCTTGGT-3’                                                 
=5’-TCCACTGGATGGTTTGTCACTGGA-3 
Human BMPR2                                                                                                              
=5’- AAAGCCCAGAAGAGCACAGA-3’ 
5’-AGCGATTCAGTGGAGATGAC-3’  
 
Human FGFR2                                                                                                             
= 5’-GGATCAAGCACGTGGAAAAGAAC-3’                                                            
=5’-GGCGATTAAGAAGACCCCTATGC-3’ 
Human FGFR3                                                                                                              
= 5’-ACGTTACCGTGCTCAAGACGGC-3’                                
=5’-AGGAAGAAGCCCACCCCG-3’ 
 
RESULTS: 
SULF1/SULF2 expression in skeletal cells of adult rat bone: Qualitative analysis 
of immunochemical labelling of adult (16 week) bone sections showed high level of 
SULF1 (Figure 1.A, B) and SULF2 (Figure 1.C) expression in osteoblasts that was 
particularly pronounced in the active osteoblasts laying down the bone adjacent to 
bone fracture (Figure 1.B).  The level of both SULFS was lower in osteocytes when 
compared with osteoblasts (Figure 1A, C) as both these antibodies have been 
demonstrated to exhibit similar staining intensities (Sahota and Dhoot 2009; Gill et 
al. 2011; Gill et al. 2012).  The specificity of SULF antibodies was confirmed by 
staining of the adjacent bone sections with pre-immune SULF2 (not shown) and pre-
immune  SULF1 serum showing no reaction (Figure 1.D) but positive reaction for 
SULF1 (Figure 1.E).   SULF1 and SULF2 expression was also observed in 
osteoclasts (Figure 1.F,J) identified from their multinuclear morphology and TRAP 
staining (Figure 1.G,H,I). Figure H at low magnification highlights the abundance of 
osteoclasts at the junction of remodelling cartilage between the hypertrophic 
chondrocytes and spongy bone, and on trabecular bone surface that express both 
SULF1 and SULF2. 
The levels of Sulf1 and Sulf2 gene expression were further examined in osteoblasts 
prepared from rat calvaria during their differentiation in vitro. RNA prepared from 
such cultures at 3, 7, 10, 13 and 17 days showed gradual increases in both Sulf1 
and Sulf2 mRNA levels using real-time quantitative PCR (Figure 2.A). Figure 2B 
illustrates differentiation with time of rat calvarial-derived osteoblasts reacted for 
alkaline phosphatase activity with fast blue stain at day 7, 14 and 21.  
Differential expression of Sulf1 and Sulf2 in differentiating mouse 
chondrogenic ATDC5 cells: To determine if levels of SULFS are modified during 
chondrocyte differentiation, we examined the expression of both Sulf1 and Sulf2 
mRNA levels during prolonged growth of ATDC5 cells undergoing differentiation 
(Figure 2C). Unlike the immunolabelling analysis of human and rat articular cartilage 
showing comparable levels of both SULF1 and SULF2 in most samples as shown in 
later figures, these two transcripts changed in opposite direction in ATDC5 cells 
concomitant with the onset of matrix mineralisation (Newton et al. 2012). Sulf1 under 
these conditions thus showed very low level expression up to day 8 after which it 
gradually increased up to day 34.  In contrast, Sulf2 was highly expressed from day 
6 after which its expression gradually decreased up to day 34 (Figure 2C). 
Sulf1/Sulf2 expression patterns in human cancellous and sub-chondral bone: 
Our recent studies have demonstrated the existence of functionally distinct Sulf1 and 
Sulf2 splice variants in some normal fetal and tumour tissues (Gill et al. 2011; Gill et 
al. 2012). To determine if the levels or nature of Sulf1 or Sulf2 variants varied in 
cancellous and sub-chondral  bone-derived osteoblasts, primers specific for each 
Sulf variant mRNA were used for RT PCR analysis  of prostaglandin E2 (PGE2) 
treated cancellous and sub-chondral bone-derived osteoblasts since the full length 
SULFs are known to inhibit VEGF activity and PGE2 treatment has been shown to 
induce VEGF production (Clarkin et al. 2008).  Both Sulf1 and Sulf2 variants were 
expressed by all osteoblasts and PGE2 treatment produced no effect on their 
relative expression levels examined by this procedure (Figure 3). The differences in 
relative levels of Sulf1 expression between some samples were more commonly 
observed with primers to catalytic region than to the hydrophilic region of Sulf1.  All 
samples showed the presence of a single major band representing full length Sulf1 
but some samples  also  showed low-abundance of a shorter band with 240bp 
deletion (indicated by arrow heads and arrows) for Sulf2 in the catalytic domain 
(Figure 3). The sequence analysis of this band confirmed it as a deletion of 240bp 
exon 6.  The level of expression of this band, however, was too low to identify 
differences between samples.  These in-vitro data are in agreement with the 
immunolabelling of bone and support an increase in SULF1 and SULF2 expression 
with osteoblast differentiation. 
Sulf1/Sulf2 expression in human cartilage: Sulf1/Sulf2 expression was also 
examined in normal human articular cartilage using splice variant specific primers.  
Full length Sulf1 and Sulf2 transcripts in human articular cartilage samples were 
expressed at variable abundance whereas the splice variants were undetectable 
(Figure 4).  The variable expression of Sulf1 and Sulf2 was not related to the age of 
the individuals but interestingly qualitative evaluation indicated that high levels of 
both Sulf1 and Sulf2 were generally found in samples that also showed  high levels 
of cyclin D1 and the cell signalling components, FGFR2, FGFR3 and BMPR2- 
receptors (Figure 4). The reason for non-detection of both Sulf1/Sulf2 and signalling 
molecules in two samples (18 & 44) is not clear but may relate to the quiescent 
nature and lack of activity in such cells. 
Heterogeneous expression of SULF1 and SULF2 in articular chondrocytes: 
Since the RT PCR analysis of human cartilage demonstrated highly variable levels of 
both Sulf1 and Sulf2, we further examined such expression at the cellular level using 
immunohistochemical labelling in rat articular cartilage.  Both SULF1 and SULF2 
were expressed by the majority of chondrocytes during development and in adult 
articular cartilage. Some chondrocytes, however,   failed to show either SULF1 or 
SULF2 labelling and the proportion of these double negative chondrocytes was 
higher postnatally compared to fetal cartilage (Figure 5).  While the expression of 
both enzymes was evenly distributed throughout the developing cartilage, their 
expression was more pronounced in the superficial and mid- zone chondrocytes in 
the adult cartilage.  
In contrast to SULF1, SULF2 is highly expressed in hypertrophic chondrocytes 
of the developing bone: Immunocytochemical staining of longitudinal sections of 
fetal, early postnatal and adult rat limb bones through growth plates demonstrated 
marked differences in the expression patterns of SULF1 and SULF2 proteins.  
SULF1 and SULF2 were expressed at relatively high levels in fetal and adult 
cartilage with SULF2 expression in greater abundance compared to SULF1 (Figure 
6). This difference was more marked at postnatal days 7 and 10 where SULF1 was 
low and restricted to punctate localization on the cell membrane in hypertrophic 
chondrocytes whereas the levels of SULF2 associated with these cells were high.  
SULF2 expression, however, was not particularly evident in the hypertrophic cell 
cytoplasm but was rather restricted to the ECM surrounding the cell membrane, 
particularly around the most mature hypertrophic chondrocytes towards the 
metaphysis. The relative expression of SULF1 (low) and SULF2 (high) was also 
observed in hypertrophic chondrocytes within secondary ossification centres (data 
not shown).  
SULF2 but not SULF1 expression in hypertrophic chondrocytes correlates with 
Hedgehog signalling in both growth plate and bone fracture healing: To 
determine if healing bone recapitulates SULF1 and SULF2 expression patterns 
observed in developing bone, we examined their localisation along with markers of 
Hedgehog signalling during post fracture bone healing (Figure 7A, A1). Examination 
of bone fracture sites 9 days post injury demonstrated some changes similar to 
developing bone but also identified the presence of some cellular structures that 
often appeared to be present in the centres of hypertrophic chondrocytes. While the 
hypertrophic chondrocytes and/or their remnants only stained for SULF2 and ptc1 
but barely for SULF1, the cellular structures located in the hypertrophic cells stained 
for all three including SULF1 (Figure 7.B-D). It was not clear if such “cells” 
represented remnants of hypertrophic chondrocytes destined to undergo apoptosis 
or some other emerging cells in this area. Further examination of other hypertrophic 
areas in the same and some other healing bones demonstrated morphology of such 
cells more akin to healthy cells and not apoptotic cells (Figure 7 E1, E2, E3).  SULF1 
staining intensity and relative proportion of this non-hypertrophic set of cells positive 
for not only SULF2 and ptc1 but also SULF1 varied in number as is apparent from 
the higher proportion of such cells in Figure 7. E1, E2 and E3.  SULF1 and SULF2 
expression in the adjacent healing bone in contrast was essentially identical as 
shown by their comparable staining intensities (not shown).   
To determine if the high levels of SULF2 expression in hypertrophic chondrocytes 
correlate with Hedhehog cell signaling, we also examined the expression of ptc1 
receptor as a marker of this signaling pathway in both bone fracture and the growth 
plate.  The immunocytochemical staining of hypertrophic chondrocytes in the growth 
plate as well as changes in hypertrophic cells during bone fracture showed the 
expression of SULF2 spreading from cell membrane to ECM closely correlating with 
ptc1 receptor but not SULF1 (Figure 7.C1, D1, E2, E3 & Figure 8). The SULF2 and 
ptc1 staining in the areas of hypertrophy clearly extended beyond cell membrane 
into ECM (Figure 7 & 8).  
 
DISCUSSION:  
Most cells exhibit a marked down regulation of SULF1 and SULF2 expression 
postnatally and seem only to re-activate expression upon injury (Sahota and Dhoot 
2009; Dhoot 2012). Our studies show that cartilage and bone cells do not follow this 
trend but instead retain an easily detectable level of both SULF1 and SULF2 
expression in postnatal and adult skeletal elements that also agrees with previous 
studies demonstrating some Sulf1/Sulf2 expression in fetal and postnatal tissues 
(Zhao et al. 2006; Otsuki et al. 2008; Ratzka et al. 2008). Previously, only adult 
neuronal tissues have been found to express high levels of these enzymes (Joy et 
al. 2015); some low level expression in endothelial cells has been documented 
where they have been shown to act as cell signalling inhibitors (Sahota and Dhoot 
2009). Continued expression of SULF1/SULF2 by chondrocytes in postnatal 
cartilage may also relate to some inhibitory role although SULF expression was not 
observed in all chondrocytes. The detection of some SULF-positive and SULF-
negative articular chondrocytes, however, indicates the varying levels of 
chondrocytic activity or quiescence.  In neuronal tissue, SULFs persist in the adult to 
inhibit cell proliferation and neurite outgrowth (Joy et al. 2015). It is not clear if the 
expression and non-detection of SULFs in a subset of cells represents activity 
versus quiescence since the chondrocytes are not known to undergo significant cell 
proliferation. The change in the levels of SULF1/SULF2 does not only relate to the 
relative proportions of positive and negative cells expressing these enzymes but also 
the expansion of the negative ECM area between these cells. Nevertheless, both 
SULF1 and SULF2 expression was detected in a sub-population of articular 
chondrocytes.  Unlike increasing expression of SULF1/SULF2 with age reported by 
Ratzka et al (Ratzka et al. 2008), we found the levels of these enzymes in adult 
human as well as rodent articular cartilage to be much lower than that observed 
during fetal development. The in vivo expression, however, was in marked contrast 
to the prolonged in vitro differentiation of chondrocytic cell line ATDC5 showing an 
increase in Sulf1 but a decrease in Sulf2.  SULF1 and SULF2 enzymes during in 
vitro differentiation of this chondrocytic cell line could thus have differential functions 
requiring activation or inhibition of specific signalling pathways.  This differed from 
the in vivo articular chondrocytes expressing fairly similar levels of both SULFs 
detected by immunocytochemistry. The differential changes in SULF1 and SULF2 
expression levels were also identified in hypertrophic chondrocytes that unlike 
ATDC5 showed up-regulation of SULF2 but down-regulation of SULF1. Not all 
chondrocytes, however, showed differential SULF1 and SULF2 changes like 
hypertrophic chondrocytes since not only articular chondrocytes but also some other 
cells observed in hypertrophic chondrocyte rich areas following fracture repair 
showed generally similar expression patterns.  
Persistent expression of SULFs in osteoblasts could relate to prolonged postnatal 
period of growth as well as bone remodelling post-growth period. This is supported 
by the high SULF levels in osteoblasts laying down the bone but with reduced levels 
in the osteocytes. The up-regulation of SULFs with differentiation is also supported 
by the RT PCR analysis of osteoblast cultures prepared from rat calvariae that also 
demonstrated comparable increases in both Sulf1 and Sulf2 during in vitro 
differentiation indicating possibly similar roles of these enzymes in bone cell 
signalling.  High SULF levels in active osteoblasts were particularly apparent during 
bone fracture healing where the SULFs could enhance specific cell signalling 
pathways such as BMP and/or Wnt signalling.   
To examine if sub-chondral osteoblasts near the vascularisation area expressed 
different levels of Sulf1 and Sulf2 or their shorter variants that could promote 
angiogenesis, we compared these cultures with cancellous bone derived osteoblasts 
in the presence and absence of PGE2 known to promote VEGF expression by such 
cells (Clarkin et al. 2008). The osteoblast cultures prepared from both cancellous 
and subchondral bone as representatives of in vivo endochondral ossification also 
demonstrated generally similar changes in Sulf1 and Sulf2 except with a slightly 
higher level expression of Sulf2 relative to Sulf1, indicating similar roles of Sulf1 and 
Sulf2 during in vitro differentiation of osteoblasts.  Osteoblasts prepared from 
cancellous and subchondral bone showed mainly full length Sulf1 and Sulf2 although 
a very low level expression of Sulf2 with 240bp exon 6 deletion was also detected in 
a number of these samples that was not significantly different in cancellous versus 
subchondral or during 3 hour incubation with 1µM PGE2. This is compatible with little 
or no expression of such variants in most postnatal tissues except during acute injury 
compared with fetal (Gill et al. 2010; Hitchins et al. 2013) and particularly tumour 
tissues (Gill et al. 2014). The requirement of only a very subtle change in the levels 
of shorter variants, not quantifiable by this method, or proximity to the hypertrophic 
chondrocytes expressing high levels of full length SULF2, which has been described 
to have some pro-angiogenic function (Morimoto-Tomita et al. 2005), may be 
sufficient to promote angiogenesis in sub-chondral bone. 
Dynamic and variable SULF1/SULF2 expression profiles highlight shared as 
well as unique roles of these enzymes. Hypertrophic chondrocytes showed the 
presence of mainly SULF2 with only low level SULF1 expression.  The presence of a 
mixture of cells following bone fracture that were positive for SULF2 but larger 
hypertrophic cells showing little or no SULF1 expression indicates that while SULF1 
and SULF2 were  segregated in hypertrophic cells, some other cells that may be 
remnants of necrotic  hypertrophic chondrocytes expressed both SULF1 and SULF2.  
This suggests that some functions may be unique to SULF1 and SULF2 but other 
functions are shared in which they could even compensate for each other. 
It is possible that hypertrophic chondrocytes that are believed to be in hypoxic 
environment at the chondro-vascular border promote angiogenesis since VEGF is 
believed to be expressed in and around hypertrophic chondrocytes of the growth 
plate (Petersen et al. 2002). Differential SULF1/SULF2 expression in hypertrophic 
chondrocytes may thus indicate their differential roles in vascularisation as has been 
suggested by the antiangiogenic activities of SULF1 (Sahota and Dhoot 2009; Wang 
et al. 2004) but a pro-angiogenic activity of SULF2 in some mammary tumours 
(Morimoto-Tomita et al. 2005). 
The spread of SULF2 enzyme to the ECM around the hypertrophic chondrocytes 
also agrees with our early report of SULF2 association with the stromal compartment 
in some tumours (Gill et al. 2014) although SULF2 detected in stromal compartment 
in such cases was produced by the inflammatory cells whereas SULF2 in 
hypertrophic chondrocyte rich areas is generated by the chondrocytes themselves 
diffusing into the surrounding ECM since no interstitial cells are observed in this 
area. This is also compatible with SULF2 secretion into the culture medium 
indicating that although both these enzymes are docked to the cell membrane they 
can also detach to diffuse into the extracellular milieu (Uchimura et al. 2006).  It is 
not clear if both SULF1 and SULF2 influence certain ligand gradients such as Shh.  
For example, Ramsbottom et al (Ramsbottom et al. 2014) recently reported SULF1 
influencing the Shh morphogen gradient during the dorsal ventral patterning of the 
neural tube in Xenopus by restricting ligand diffusion whereas Sulf1 knockdown 
resulted in a more diffuse distribution of Shh ligand.  SULF2 thus could also modify 
the sulfation of heparan sulfate of HSPGs extracellularly to regulate the bio-
availability of Hedgehog ligand for Hedgehog/ptc1 cell signalling or indeed any other 
signalling ligand such as Wnt.  This could also modulate the ligand interaction with 
glypicans to facilitate Hedgehog signalling as has been reported for Wnt signalling 
(Ai et al. 2003).  As was the case with SULF2, ptc1, a hedgehog receptor was 
detected not only on the cell membrane but also in the ECM.  Cell surface receptors 
are usually embedded in the cell membrane and therefore restricted to the site of cell 
signalling only. It is possible that ptc1 could diffuse into ECM if it is processed in this 
compartment to be used as an inhibitor, as, for example, has been described for 
endoglin.  Indeed, ptc1 has been reported to sequester hedgehog ligand and restrict 
its movement to generate hedgehog morphogen gradients (Dessaud et al. 2007).  
These data suggest possible roles for SULFs in controlling Hedgehog signalling and 
unique functional roles for secreted SULF2 in the ECM. Since a number of growth 
factors are expressed during different phases of fracture-healing, the role of SULF1 
and SULF2 molecules could be important as potential therapeutic agents to enhance 
their signalling, bone repair or to accelerate fracture-healing.  
 
FIGURE LEGENDS: 
Figure 1: SULF1/SULF2 cellular expression in some rat skeletal elements: Sections 
of normal adult rat bone (A, C, F, J) and post-fracture healing bone tissues (B, D, E) 
stained with antibodies to SULF1, SULF2 and preimmune serum using 
immunofluorescence (A,B,D,E,F) and immunoperoxidase (C, J ) procedures as well 
as TRAP2 staining for osteoclasts (F,H,I) to confirm Sulf expression in such cells; ob 
= osteoblasts, ocy =osteocytes. Figure H at low magnification indicates the location 
of higher concentration of osteoclasts at the junction of remodelling cartilage near 
the hypertrophic chondrocytes and at the surface of trabecular bone while higher 
magnification in I & J confirms the location of SULF1/SULF2 in such multinuclear 
cells. 
Figure 2: A & B-: Osteoblasts prepared from rat calvaria grown in vitro up to 17days 
for  qPCR analysis (A) and cells grown for 1, 2 and 3 weeks for differentiation 
staining for alkaline phosphatase activity with fast blue stain (B). C: qPCR analysis of 
ATDC5 mouse cells grown in vitro for upto 34 days for changes in Sulf1 and Sulf2 
mRNA levels during differentiation. 
Figure 3: Osteoblasts prepared from human cancellous and sub-chondral bone 
cultured in the absence and presence of PGE2 for 3 hours before RT PCR analysis 
for Sulf1 and Sulf2 expression with normalisation using β-actin levels.  For Sulf2, a 
full length main band and a faint shorter band with exon 6 deletion are pointed by the 
arrows or arrow heads.   
Figure 4: The use of RNA from growing, adult and ageing human articular cartilage 
used for RT PCR analysis of Sulf1 and Sulf2 representing both catalytic and 
hydrophilic domains and their correlation with BMPR2, CyclinD1, FGFR2 and 
FGFR3 with normalisation using β-actin primers. The numbers in the top lane refer to 
age in years.  
Figure 5:  The immunofluorescence staining of paraffin sections through articular 
cartilage region of 17 day fetal, 7d postnatal and 3 month old rat with antibodies to 
SULF1 and SULF2.  Also included is a magnified region in the bottom left hand 
corner of each image with some negative chondrocytes pointed out by arrows. Blue 
DAPI stains all nuclei. 
Figure 6: The immunofluorescence staining of paraffin sections through the growth 
plate of 17.5 day fetal, 7d and 10d postnatal and 3-month old rat limbs with 
antibodies to SULF1 and SULF2.  Also included is a magnified region through the 
hypertrophic chondrocyte area in the bottom left hand corner of each image. Blue 
DAPI stains all nuclei. 
Figure 7: The H & E (A) staining and immunofluorescence staining of paraffin 
sections through healing bone 9 day post fracture with antibodies to SULF1 (B), 
SULF2 (C) and ptc1 (D) at low and high magnification (A1, B1, C1, D1).  The 
rectangle shown in A-D indicates the selected area magnified in A1-D1.  To highlight 
cell morphology, also included is a small section of further magnification shown in 
the bottom right hand corner of A1, B1, C1 and D1. White lines in B, C and D 
indicate the morphological landmarks in different sections to highlight the differences 
in SULF1, SULF2 and ptc1 staining.  Blue DAPI stains all nuclei.  White arrows point 
to “cells” stained for not only SULF2 and ptc1 but also SULF1.  Green lines point to 
the hypertrophic chondrocytes stained for SULF2 and ptc1 but not SULF1.  E1, E2 
and E3 are sections through another region of bone healing 9d post fracture stained 
for SULF1, SULF2 and ptc1 to highlight the presence of a number of “cells” staining 
(pointed out by some arrows) with all three antibodies.  
Figure 8: Sections through growth plate of 7d postnatal rat tibia and 14 day post 
fracture healing femur stained for SULF1, SULF2 and ptc1 to highlight the correlation 
of SULF2 staining of hypertrophic chondrocytes with ptc1 in both growth plate and 
healing bone.  
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